Latest News

Unleashad

European_Commission.svg

TILT won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument. The grant will be used to perform a Phase 1 clinical trial with the company’s lead drug, TILT-123. Read the press release here.

Latest News

Upcoming Events

Please contact our business development team to meet us at the following events:

7-9th December 2022
Geneva, Switzerland
20-22nd March 2023
Basel, Switzerland
15–16th May 2023
Dublin, Ireland
5-8th June 2023
Boston (MA), USA
2-6th June 2023
Chicago (IL), USA